Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

NCT04122911 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinomas

Interventions

DRUG: Temozolomide

Sponsor

National Cancer Institute, Naples